Cyclacel Pharmaceuticals, Inc. (CYCC)

Cyclacel Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	2	2	8	39	38	12
Market Cap Growth	-61.12%	-73.09%	-78.45%	2.15%	229.64%	52.41%
Enterprise Value	-0	-1	-10	2	6	1
PE Ratio	-	-0.10	-0.39	-2.08	-3.06	-1.43
PS Ratio	5.44	5.36	-	-	-	-
PB Ratio	-1.26	3.71	0.53	1.03	1.14	0.99
P/FCF Ratio	-0.29	-0.14	-0.40	-2.09	-4.73	-1.22
P/OCF Ratio	-0.29	-0.14	-0.40	-2.09	-4.79	-1.22
EV/Sales Ratio	0.01	-2.60	-	-	-	-
EV/EBITDA Ratio	0.00	0.04	0.38	-0.10	-0.58	-0.09
EV/EBIT Ratio	0.00	0.04	0.38	-0.10	-0.58	-0.09
EV/FCF Ratio	0.00	0.07	0.47	-0.12	-0.70	-0.09
Debt / Equity Ratio	-0.01	0.06	0.01	0.00	0.03	0.10
Debt / EBITDA Ratio	0.00	0.00	0.00	0.00	-0.11	-0.13
Debt / FCF Ratio	0.00	0.00	-0.01	0.00	-0.13	-0.13
Quick Ratio	0.34	0.41	2.44	6.75	13.44	4.91
Current Ratio	0.58	0.91	3.25	7.56	14.27	5.79
Asset Turnover	0.04	0.03	0	0	0	0
Return on Equity (ROE)	-1013.40%	-450.90%	-84.20%	-43.80%	-52.50%	-54.60%
Return on Assets (ROA)	-180.80%	-152.20%	-63.90%	-40.10%	-46.80%	-43.80%
Return on Capital (ROIC)	1029.24%	-3952.33%	-172.37%	-59.35%	-30.99%	-75.12%
Earnings Yield	-812.19%	-1011.19%	-255.86%	-48.08%	-32.70%	-69.69%
FCF Yield	-398.34%	-716.22%	-249.10%	-47.85%	-21.14%	-81.73%
Buyback Yield / Dilution	-57.70%	-12.32%	-26.10%	-145.67%	-345.23%	-34.95%
Total Shareholder Return	-57.70%	-12.32%	-26.10%	-145.67%	-345.23%	-34.95%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).